{"id":"https://openalex.org/W2995691940","doi":null,"title":"Novel Strategies for Combatting Acquired Resistance to Combined BRAF and MEK Inhibition in Mutant BRAF Melanomas","display_name":"Novel Strategies for Combatting Acquired Resistance to Combined BRAF and MEK Inhibition in Mutant BRAF Melanomas","alternate_titles":[],"publication_year":2019,"publication_date":"2019-01-01","ids":{"openalex":"https://openalex.org/W2995691940","mag":"2995691940"},"language":"en","primary_location":{"id":"pmh:oai:jdc.jefferson.edu:dissertations-1420","doi":null,"is_oa":true,"landing_page_url":"https://jdc.jefferson.edu/dissertations/AAI27663548","pdf_url":null,"source":{"id":"https://openalex.org/S4210178181","display_name":"The Medicine Forum","issn_l":"2325-2863","issn":["2325-2863"],"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ProQuest ETD Collection - Thomas Jefferson University","raw_type":"text"},"parent_works":[],"lineage":["https://openalex.org/W2995691940"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://jdc.jefferson.edu/dissertations/AAI27663548","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5021339320","display_name":"Ileine M. Sanchez","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Ileine M. Sanchez","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5021339320"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.7419999837875366},{"id":"https://openalex.org/keywords/braf-mutation","display_name":"BRAF mutation","score":0.6909999847412109},{"id":"https://openalex.org/keywords/mek-inhibition","display_name":"MEK inhibition","score":0.7580000162124634},{"id":"https://openalex.org/keywords/acquired-drug-resistance","display_name":"acquired drug resistance","score":0.8709999918937683},{"id":"https://openalex.org/keywords/combination-targeted-therapy","display_name":"combination targeted therapy","score":0.718999981880188},{"id":"https://openalex.org/keywords/erk-signaling","display_name":"ERK signaling","score":0.8769999742507935},{"id":"https://openalex.org/keywords/plk1","display_name":"PLK1","score":0.8809999823570251},{"id":"https://openalex.org/keywords/plk1-inhibition","display_name":"PLK1 inhibition","score":0.9620000123977661},{"id":"https://openalex.org/keywords/pyroptosis","display_name":"pyroptosis","score":0.8379999995231628},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.4869999885559082},{"id":"https://openalex.org/keywords/immune-checkpoint","display_name":"immune checkpoint","score":0.47099998593330383},{"id":"https://openalex.org/keywords/syngeneic-mouse-model","display_name":"syngeneic mouse model","score":0.8569999933242798},{"id":"https://openalex.org/keywords/intermittent-dosing","display_name":"intermittent dosing","score":0.8289999961853027},{"id":"https://openalex.org/keywords/salvage-therapy","display_name":"salvage therapy","score":0.7450000047683716}],"concepts":[{"id":"https://openalex.org/C143065580","wikidata":"https://www.wikidata.org/wiki/Q3285695","display_name":"Mutant","level":3,"score":0.6264746189117432},{"id":"https://openalex.org/C2994294914","wikidata":"https://www.wikidata.org/wiki/Q1645075","display_name":"Acquired resistance","level":3,"score":0.6086254119873047},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.5501191020011902},{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.4573999047279358},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.45206061005592346},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.44173768162727356},{"id":"https://openalex.org/C2778472372","wikidata":"https://www.wikidata.org/wiki/Q7833138","display_name":"Trametinib","level":4,"score":0.41616901755332947},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.41102200746536255},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.32267290353775024},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.26983827352523804},{"id":"https://openalex.org/C114851261","wikidata":"https://www.wikidata.org/wiki/Q12147416","display_name":"Drug resistance","level":2,"score":0.2447737157344818},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.19855859875679016},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.1963190734386444},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.16245710849761963},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.1373482644557953},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.07488718628883362}],"mesh":[],"locations_count":2,"locations":[{"id":"pmh:oai:jdc.jefferson.edu:dissertations-1420","doi":null,"is_oa":true,"landing_page_url":"https://jdc.jefferson.edu/dissertations/AAI27663548","pdf_url":null,"source":{"id":"https://openalex.org/S4210178181","display_name":"The Medicine Forum","issn_l":"2325-2863","issn":["2325-2863"],"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ProQuest ETD Collection - Thomas Jefferson University","raw_type":"text"},{"id":"mag:2995691940","doi":null,"is_oa":false,"landing_page_url":"https://jdc.jefferson.edu/cgi/viewcontent.cgi?article=1420&context=dissertations","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":{"id":"pmh:oai:jdc.jefferson.edu:dissertations-1420","doi":null,"is_oa":true,"landing_page_url":"https://jdc.jefferson.edu/dissertations/AAI27663548","pdf_url":null,"source":{"id":"https://openalex.org/S4210178181","display_name":"The Medicine Forum","issn_l":"2325-2863","issn":["2325-2863"],"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ProQuest ETD Collection - Thomas Jefferson University","raw_type":"text"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2955071179","https://openalex.org/W4252868328","https://openalex.org/W1546835108","https://openalex.org/W1990511191","https://openalex.org/W1980906814","https://openalex.org/W4399128087","https://openalex.org/W2759091821","https://openalex.org/W2947157850","https://openalex.org/W2401574182","https://openalex.org/W1970039331"],"abstract_inverted_index":{"The":[0],"melanoma":[1,79,257],"treatment":[2,36,100,175,259],"landscape":[3],"has":[4],"been":[5],"revolutionized":[6],"by":[7,22,59],"the":[8,15,19,24,45,50,53,60,127],"rational":[9],"design":[10],"of":[11,18,47,52,62,106,121,137,155,170,183,235],"small":[12],"molecules":[13],"targeting":[14],"genetic":[16],"drivers":[17],"disease":[20],"and":[21,85,97,111,140,145,178,227,232,249],"harnessing":[23],"immune":[25],"system":[26],"to":[27,71,108,126,142,161,229],"attack":[28],"aberrantly":[29],"growing":[30],"cells.":[31],"Despite":[32],"dramatic":[33,54],"advancements,":[34],"both":[35],"modalities":[37],"have":[38],"limitations":[39],"that":[40,152,221,252],"mitigate":[41],"clinical":[42],"success.":[43],"In":[44],"case":[46],"targeted":[48,230],"therapies,":[49],"durability":[51],"initial":[55],"response":[56,160,226],"is":[57,129,191],"hampered":[58],"acquisition":[61],"one":[63,93],"or":[64,260],"more":[65],"resistance":[66,107,125,141],"mechanisms":[67,105],"which":[68],"allow":[69],"tumors":[70],"grow":[72],"on":[73,75,247,263],"while":[74],"treatment.":[76],"Mutant":[77],"BRAF":[78,84,109,113,144,177,210,264],"patients":[80],"treated":[81,194],"with":[82,176,204],"combined":[83,112,143],"MEK":[86,115,146,179,266],"inhibitors":[87,116,180],"can":[88],"expect":[89],"regression":[90],"for":[91],"about":[92],"year":[94],"before":[95],"relapse,":[96],"effective":[98],"salvage":[99,241],"options":[101],"are":[102],"lacking.":[103],"Acquired":[104],"monotherapy":[110],"plus":[114,265],"most":[117],"often":[118],"implicate":[119],"re-activation":[120],"MEK-ERK1/2":[122],"signaling,":[123],"although":[124],"combination":[128,203],"less":[130],"studied.":[131],"Using":[132,207],"an":[133],"in":[134,172,193,202,225,256],"vivo":[135],"model":[136],"ERK1/2":[138,156],"activity":[139,157],"inhibition,":[147],"we":[148,215],"provide":[149,245],"pre-clinical":[150],"proof-of-concept":[151],"temporal":[153],"monitoring":[154],"models":[158],"tumor":[159,219],"clinically":[162],"used":[163],"intermittent":[164],"dosing":[165],"schedules.":[166],"Proteomic":[167],"pathway":[168],"analysis":[169],"changes":[171,224],"expression":[173,182],"during":[174,258],"indicated":[181],"cell":[184],"mitotic":[185],"regulator":[186],"polo-like":[187],"kinase":[188],"1":[189],"(Plk1)":[190],"maintained":[192],"resistant":[195,205],"melanomas.":[196,206],"Plk1":[197],"inhibition":[198],"selectively":[199],"induced":[200],"apoptosis":[201],"a":[208,239],"mutant":[209],"syngeneic":[211],"immune-competent":[212],"mouse":[213],"model,":[214],"also":[216],"identified":[217],"intrinsic":[218],"alterations":[220],"drove":[222],"immune-dependent":[223],"relapse":[228],"therapy,":[231],"demonstrate":[233],"induction":[234],"pyroptotic":[236],"death":[237],"as":[238],"novel":[240],"therapy.":[242],"These":[243],"data":[244],"insight":[246],"strategic":[248],"therapeutic":[250],"opportunities":[251],"may":[253],"be":[254],"employed":[255],"after":[261],"progression":[262],"inhibitors.":[267]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2995691940","counts_by_year":[],"updated_date":"2026-08-01T09:00:35.917206","created_date":"2019-12-26T00:00:00"}
